Msd Merck Co Company Profile

What is the competitive landscape for MSD MERCK CO, and what generic alternatives to MSD MERCK CO drugs are available?

MSD MERCK CO has five approved drugs.

There are five US patents protecting MSD MERCK CO drugs.

There are one hundred and eighty-nine patent family members on MSD MERCK CO drugs in fifty-one countries and eighty-eight supplementary protection certificates in sixteen countries.

Summary for Msd Merck Co

International Patents:	189
US Patents:	5
Tradenames:	5
Ingredients:	5
NDAs:	5

Drugs and US Patents for Msd Merck Co

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Msd Merck Co	RECARBRIO	cilastatin sodium; imipenem; relebactam	POWDER;INTRAVENOUS	212819-001	Jul 16, 2019		RX	Yes	Yes	8,487,093		Y	Y
Msd Merck Co	PIFELTRO	doravirine	TABLET;ORAL	210806-001	Aug 30, 2018		RX	Yes	Yes	8,486,975		Y	Y
Msd Merck Co	NOXAFIL POWDERMIX KIT	posaconazole	FOR SUSPENSION, DELAYED RELEASE;ORAL	214770-001	May 31, 2021		RX	Yes	Yes
Msd Merck Co	DELSTRIGO	doravirine; lamivudine; tenofovir disoproxil fumarate	TABLET;ORAL	210807-001	Aug 30, 2018		RX	Yes	Yes	10,842,751		Y
Msd Merck Co	PIFELTRO	doravirine	TABLET;ORAL	210806-001	Aug 30, 2018		RX	Yes	Yes
Msd Merck Co	RECARBRIO	cilastatin sodium; imipenem; relebactam	POWDER;INTRAVENOUS	212819-001	Jul 16, 2019		RX	Yes	Yes

Expired US Patents for Msd Merck Co

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Msd Merck Co	EMEND	aprepitant	FOR SUSPENSION;ORAL	207865-001	Dec 17, 2015	6,096,742

Paragraph IV (Patent) Challenges for MSD MERCK CO drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Injection	115 mg/vial		2012-01-25
	for Oral Suspension	125 mg/Kit		2016-11-23
	Capsule	40 mg, 80 mg and 125 mg		2008-11-03
	Injection	150 mg/vial		2012-01-25

International Patents for Msd Merck Co Drugs

Country	Patent Number	Estimated Expiration
Ukraine	76810
Ecuador	SP045144
Croatia	P20131123
World Intellectual Property Organization (WIPO)	2017095761
World Intellectual Property Organization (WIPO)	03049718
Japan	2011510012

Supplementary Protection Certificates for Msd Merck Co Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2666774	2020024	Norway		PRODUCT NAME: KOMBINASJON AV RELEBAKTAM EVENTUELT I FORM AV MONOHYDRAT, IMIPENEM OG CILASTATIN, EVENTUELT I FORM AV NATRIUMSALT; REG. NO/DATE: EU/1/19/1420 20200219
2666774	301051	Netherlands		DETAILS ASSIGNMENT: CHANGE OF OWNER(S), MERGE
2924034	132019000000062	Italy		PRODUCT NAME: DORAVIRINA O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE IN COMBINAZIONE CON LAMIVUDINA O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE IN COMBINAZIONE CON TENOFOVIR O UN SUO ESTERE, IN PARTICOLARE UN ESTERE DI DISOPROXIL O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE, IN PARTICOLARE UN SALE FUMARATO(DELSTRIGO); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/18/1333/001-002, 20181127
2666774	132020000000073	Italy		PRODUCT NAME: RELEBACTAM, OPZIONALMENTE IN FORMA DEL MONOIDRATO, IMIPENEM E CILASTATINA, OPZIONALMENTE NELLA FORMA DEL SALE SODICO(RECARBRIO); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/19/1420, 20200217
2231667	30/2020	Austria		PRODUCT NAME: RELEBACTAM ODER EIN MONOHYDRAT DAVON; REGISTRATION NO/DATE: EU/1/19/1420 (MITTEILUNG) 20200217
0734381	PA2004002,C0734381	Lithuania		PRODUCT NAME: 5-(((2R,3S)-2-((1R)-1-(3,5-BIS(TRIFLUORMETIL)FENIL)ETOKSI)-3-(4-FLUORFENIL)-4-MORFOLINIL)METIL)-1,2-DIHIDRO-3H-1,2,4-TRIAZOL-3-ONAS (APREPITANTAS); REGISTRATION NO/DATE: EU/1/03/262/001, 2003 11 11, EU/1/03/262/002, 2003 11 11, EU/1/03/262/003, 2003 11 11, EU/1/03/262/004, 2003 11 11, EU/1/03/262/005, 2003 11 11, EU/1/03/262/006 20031111

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Msd Merck Co
• Msd Sub Merck